Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning

TY - JOUR

T1 - Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission

T2 - single-centre results after TBI-based myeloablative and non-myeloablative conditioning

AU - Sengeløv, H

AU - Gerds, T A

AU - Brændstrup, P

AU - Kornblit, B

AU - Mortensen, B K

AU - Petersen, S L

AU - Vindeløv, L L

PY - 2013/9

Y1 - 2013/9

N2 - We report the results of non-myeloablative (NM) and myeloablative (MA) conditioning for haematopoietic cell transplantation in 207 consecutive AML patients at a single institution. A total of 122 patients were transplanted in first CR (CR1) and 67 in second CR (CR2). MA conditioning was given to 60 patients in CR1 and 50 in CR2. NM conditioning was given to 62 patients in CR1 and 17 patients in CR2. MA patients in CR1 experienced more acute GVHD than NM patients, 60.5% versus 22.9%, but the 5-year post transplant cumulative TRM was not different. Relapse incidence at 5 years in CR1 patients was 23.7% which is not statistically different from 28.5% in NM patients. Leukaemia-free survival at 5 years in CR1 patients was 57.7% after MA conditioning and 58.3% after NM conditioning. No statistical difference in overall 5-year survival after MA or NM conditioning was observed in CR1 patients (63.9 versus 64%) and CR2 patients (51.2 versus 64.7%). Durable remission can be obtained in older patients with AML in remission after NM conditioning, which may also be applicable to younger patients.

AB - We report the results of non-myeloablative (NM) and myeloablative (MA) conditioning for haematopoietic cell transplantation in 207 consecutive AML patients at a single institution. A total of 122 patients were transplanted in first CR (CR1) and 67 in second CR (CR2). MA conditioning was given to 60 patients in CR1 and 50 in CR2. NM conditioning was given to 62 patients in CR1 and 17 patients in CR2. MA patients in CR1 experienced more acute GVHD than NM patients, 60.5% versus 22.9%, but the 5-year post transplant cumulative TRM was not different. Relapse incidence at 5 years in CR1 patients was 23.7% which is not statistically different from 28.5% in NM patients. Leukaemia-free survival at 5 years in CR1 patients was 57.7% after MA conditioning and 58.3% after NM conditioning. No statistical difference in overall 5-year survival after MA or NM conditioning was observed in CR1 patients (63.9 versus 64%) and CR2 patients (51.2 versus 64.7%). Durable remission can be obtained in older patients with AML in remission after NM conditioning, which may also be applicable to younger patients.

KW - Adolescent

KW - Adult

KW - Combined Modality Therapy

KW - Cyclophosphamide

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Living Donors

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Retrospective Studies

KW - Survivors

KW - Transplantation Conditioning

KW - Transplantation, Homologous

KW - Whole-Body Irradiation

KW - Young Adult

U2 - 10.1038/bmt.2013.38

DO - 10.1038/bmt.2013.38

M3 - Journal article

C2 - 23524638

SN - 0268-3369

VL - 48

SP - 1185

EP - 1191

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 9

ER -